A phase I double blind placebo controlled trial to evaluate the safety and immunogenicity of the Aventis Pasteur ALVAC-HIV (vCP205) administered to the groin area versus the deltoid area

Trial Profile

A phase I double blind placebo controlled trial to evaluate the safety and immunogenicity of the Aventis Pasteur ALVAC-HIV (vCP205) administered to the groin area versus the deltoid area

Completed
Phase of Trial: Phase I

Latest Information Update: 26 Oct 2012

At a glance

  • Drugs HIV vaccine vCP205 (Primary)
  • Indications HIV-1 infections
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 16 Sep 2008 Actual start date added (June 2006) as reported by ClinicalTrials.gov.
    • 16 Sep 2008 Planned end date added (1 Sep 2008) as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top